Immunotherapy with NK cells: recent developments in gene modification open up new avenues.
Oncoimmunology
; 9(1): 1777651, 2020 09 02.
Article
en En
| MEDLINE
| ID: mdl-33457093
ABSTRACT
Chimeric antigen receptor (CAR)-T cell therapies have achieved remarkable success. However, application-related toxicities, such as cytokine release syndrome or neurotoxicity, moved natural killer (NK) cells into focus as novel players in immunotherapy. CAR-NK cells provide an advantageous dual killing-capacity by CAR-dependent and -independent mechanisms and induce few side effects. While the majority of trials still use CAR-T cells, CAR-NK cell trials are on the rise with 19 ongoing studies worldwide. This review illuminates the current state of research and clinical application of CAR-NK cells, as well as future developmental potential.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Células Asesinas Naturales
/
Receptores de Antígenos de Linfocitos T
Límite:
Humans
Idioma:
En
Revista:
Oncoimmunology
Año:
2020
Tipo del documento:
Article
País de afiliación:
Alemania